STOCK TITAN

MacroGenics (MGNX) SVP Ezio Bonvini converts RSUs and withholds shares

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

MacroGenics Inc. insider activity: Sr VP, Research & CSO Ezio Bonvini reported routine equity transactions on February 7 and 8, 2026 involving restricted stock units (RSUs) and common stock of MacroGenics Inc. (MGNX).

On February 7, RSUs converting on a one-for-one basis were exercised for 7,001 shares of common stock, increasing his directly held common stock to 131,415 shares, while 2,703 shares were withheld at a price of $1.81 per share, leaving 128,712 shares directly owned. On February 8, an additional 11,166 RSUs were exercised into common stock, bringing direct common stock holdings to 139,878 shares before 4,311 shares were withheld at $1.81 per share, resulting in 135,567 directly owned common shares.

Following these transactions, Bonvini also held 13,999 RSUs from a February 7, 2025 grant of 21,000 RSUs vesting in three equal installments and 11,166 RSUs from a February 8, 2024 grant of 33,500 RSUs, also vesting in three equal installments beginning on the first anniversary of each grant date.

Positive

  • None.

Negative

  • None.
Insider Bonvini Ezio
Role Sr VP, Research & CSO
Type Security Shares Price Value
Exercise Restricted Stock Unit 11,166 $0.00 --
Exercise Common Stock 11,166 $0.00 --
Tax Withholding Common Stock 4,311 $1.81 $8K
Exercise Restricted Stock Unit 7,001 $0.00 --
Exercise Common Stock 7,001 $0.00 --
Tax Withholding Common Stock 2,703 $1.81 $5K
Holdings After Transaction: Restricted Stock Unit — 11,166 shares (Direct); Common Stock — 139,878 shares (Direct)
Footnotes (1)
  1. Restricted stock units convert into the Company's stock on a one-for-one basis. On February 7, 2025, the reporting person was granted 21,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date. On February 8, 2024, the reporting person was granted 33,500 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bonvini Ezio

(Last) (First) (Middle)
9704 MEDICAL CENTER DRIVE

(Street)
ROCKVILLE MD 20850

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Sr VP, Research & CSO
3. Date of Earliest Transaction (Month/Day/Year)
02/07/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/07/2026 M 7,001 A (1) 131,415 D
Common Stock 02/07/2026 F 2,703 D $1.81 128,712 D
Common Stock 02/08/2026 M 11,166 A (1) 139,878 D
Common Stock 02/08/2026 F 4,311 D $1.81 135,567 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 02/07/2026 M 7,001 (2) (2) Common Stock 7,001 $0 13,999 D
Restricted Stock Unit (1) 02/08/2026 M 11,166 (3) (3) Common Stock 11,166 $0 11,166 D
Explanation of Responses:
1. Restricted stock units convert into the Company's stock on a one-for-one basis.
2. On February 7, 2025, the reporting person was granted 21,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date.
3. On February 8, 2024, the reporting person was granted 33,500 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date.
Remarks:
/s/ Beth A. Smith, Attorney-in-fact 02/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MacroGenics (MGNX) report for Ezio Bonvini on February 7–8, 2026?

Ezio Bonvini exercised restricted stock units into common stock on February 7 and 8, 2026, and had shares withheld to cover obligations. He acquired 7,001 and 11,166 common shares through RSU conversions and had 2,703 and 4,311 shares withheld at $1.81 per share.

How many MacroGenics (MGNX) shares does Ezio Bonvini own after the February 2026 Form 4 transactions?

After the reported transactions, Ezio Bonvini directly owns 135,567 shares of MacroGenics common stock. This figure reflects RSU conversions into common stock on February 7 and 8, 2026, and subsequent share withholdings at a price of $1.81 per share.

What restricted stock unit (RSU) grants are disclosed for Ezio Bonvini in the MacroGenics (MGNX) Form 4?

The filing shows a February 7, 2025 grant of 21,000 RSUs and a February 8, 2024 grant of 33,500 RSUs. Each grant vests in three equal installments beginning on the first anniversary of its grant date and converts into common stock on a one-for-one basis.

What do the transaction codes M and F mean in the MacroGenics (MGNX) Form 4 for Ezio Bonvini?

Code M indicates the exercise or conversion of derivative securities, here restricted stock units converting into common stock at $0 per share. Code F represents shares of common stock withheld at $1.81 per share, typically to satisfy related obligations associated with those equity awards.

What prices were used for share withholdings in Ezio Bonvini’s MacroGenics (MGNX) Form 4?

For both February 7 and 8, 2026 transactions, shares of MacroGenics common stock were withheld at a price of $1.81 per share. On those dates, 2,703 and 4,311 shares, respectively, were withheld under transaction code F following RSU conversions.

How many restricted stock units does Ezio Bonvini hold after the February 2026 MacroGenics (MGNX) transactions?

Following the RSU conversions, the report shows 13,999 restricted stock units remaining from the February 7, 2025 grant and 11,166 restricted stock units from the February 8, 2024 grant. Each RSU converts into one share of MacroGenics common stock upon settlement.